A new Neurolixis method-of-use patent has issued in the USA, expanding protection of NLX-112 for treatment of movement disorders. Specifically, the patent covers the use of NLX-112 to treat side-effects induced by tetrabenazine (a drug that targets brain vesicular monoamine transporters, VMAT) in patients suffering from hyperkinetic disorders such as Huntington’s disease. Tetrabenazine reduces the hyperkinesia, also known as chorea, but has a high incidence of depression and parkinsonism side-effects. In animal models, NLX-112 and related compounds reversed both of these side effects of tetrabenazine, suggesting that it could improve management of Huntington's disease and, potentially, other hyperkinetic disorders.
See full patent here: https://bit.ly/356T3bJ

NLX-112 is currently undergoing a Phase 2A clinical trial for treatment of L-DOPA-induced dyskinesia in Parkinson’s disease (see previous press release).



Please enable the javascript to submit this form

Follow Neurolixis on: